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Abstract
Background: The Platelet Inhibition and Patient Outcomes (PLATO, Eur J Prev Cardiol 22(6):734–42, 2015) trial shows
that, in patients who have an acute coronary syndrome, treatment with ticagrelor as compared with clopidogrel
significantly reduced the rate of death, but the reason is still uncertain. Both inflammation and vascular endothelian cell
dysfunction play important roles in the pathophysiology of atherosclerotic plaques, but whether ticagrelor has superior
anti-inflammatory effect and can improve vascular endothelial cell function to a great extent is unknown.
Methods/design: Patients with STEMI who are scheduled to undergo emergency percutaneous coronary
intervention (PCI) will be randomly assigned to receive a loading dose of ticagrelor 180 mg as the treatment group
or clopidogrel 600 mg as the control group. After PCI, the treatment group will be treated with ticagrelor 90 mg
twice daily while the control group will be treated with clopidogrel 75 mg once daily. The vascular endothelial
function will be tested by circulating endothelial cells, and levels of inflammation will be tested by CD40 ligand
(CD40L), high sensitivity C-reactive protein (hsCRP) and P-selectin. The estimated enrollment sample size will be 350
patients, including 175 in the treatment group and 175 in the control group.
Discussion: This study will compare the influence of ticagrelor and clopidogrel on inflammatory biomarkers and
vascular endothelial function firstly for STEMI patients receiving emergency PCI and will provide evidence to identify
whether ticagrelor inhibits inflammation and improves vascular endothelial cell function to a greater extent than
clopidogrel or not.
Trial registration: This trial was registered with Clinicaltrials.gov (identifier: NCT02123004) on 20 April 2014.
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Background
Acute myocardial infarction (AMI) is a serious illness haz-
ard to human health and has a high mortality rate. It has
been shown that atherosclerotic plaque rupture causes
serious clinical events. In recent years, the criminal vascular
patency rate has been significantly improved by applying
emergency PCI treatment, but it is still lacking in restor-
ation and protection of damaged myocardium. Inflamma-
tion is a key factor in the development of atherosclerotic
disease and acute coronary syndrome (ACS) [2–5]. Cur-
rently, it is considered that plaque rupture caused by the
joint action of inflammation and vascular endothelial cell
dysfunction leads to AMI, and the concentration of in-
flammatory markers is closely related to the degree of in-
stability and progression of atherosclerotic plaque [6]. In
the review published in Nature Medicine, hypercholester-
olemia and inflammation were described as “partners in
crime” [7]. Therefore, under the premise of recanalization
of occlusions and revascularization, regulating inflamma-
tory reactions of lesions is the key to improving the prog-
nosis of patients with AMI.
Platelets participate in the process of forming and ex-
tending atherosclerotic plaques, and are a source of in-
flammatory mediators [8]. The activation of platelets by
inflammatory triggers may be a critical component of ath-
erothrombosis [9]. Now more and more evidence has
proven that the processes of inflammation and thrombosis
are closely related [10, 11]. Since platelet activation, throm-
bosis and inflammation are closely linked, effective platelet
inhibition may also bring about an anti-inflammatory ef-
fect. Therefore, anti-platelet medicines should have other
functions in addition to anticoagulant effects, and it has
been shown that they have direct or indirect anti-
inflammatory effects in vitro or in vivo [12–14].
Studies have shown that aspirin can inhibit transform-
ing growth factor-β and proliferation of vascular smooth
muscle cell [15, 16], and it is able to lower the activity of
nuclear factor-κB, which is necessary in coding proin-
flammatory mediators such as monocyte chemoattract-
ant protein-1 and interleukin-8 [17, 18].
Independent of the loading or maintenance dose,
patients treated with prasugrel, one of the antiplatelet
medicines, exhibited significantly more potent platelet in-
hibition as determined by adenosine diphosphate, and
collagen-induced aggregation, Ultegra Analyser measure-
ments, and surface expression of platelet endothelial cell
adhesion molecule-1, platelet glycoproteinIIb/IIIa antigen,
and activity with procaspase activating compound-1 anti-
body, glycoprotein Ib, P-selectin, CD40L, platelet glyco-
protein 37, and thrombospondin receptor expression
when compared with those treated with clopidogrel [19].
Prasugrel use with a 60 mg loading dose and 10 mg main-
tenance dose inhibits several markers of platelet activation
and the formation of platelet-monocyte aggregates more
effectively than a 600 mg loading dose and 75 mg main-
tenance dose of clopidogrel [20].
Another antiplatelet medicine, clopidogrel, has been
proved to lower the activities of, for example, inflamma-
tory cytokines, C-reactive protein (CRP), and P-selectin
[12, 13, 21–24]. There is also substantial evidence that
therapy with clopidogrel can lead to reductions in serum
levels of CD40L, CRP, P-selectin, and platelet-leukocyte
aggregate formation in patients with ischemic vascular
disease, especially in patients with ACS receiving PCI
[25]. Chen et al. compared aspirin alone with aspirin
plus clopidogrel (loading dose of clopidogrel 300 mg,
followed by clopidogrel 75 mg daily) for effects on high
sensitivity C-reactive protein (hsCRP) in 115 patients
with non-ST-segment elevation acute coronary syn-
drome (NSTE-ACS) [26]. Mean CRP levels were reduced
at both 7 and 30 days in both groups, and clopidogrel
was significantly more effective than aspirin alone in
lowering CRP.
Integrity loss of vascular endothelial cells is considered to
be a consistent factor of atherosclerotic plaque rupture and
non-atherosclerotic vascular wall rupture events [27–29].
The number of circulating endothelial cells (CECs) in many
vascular injury diseases is significantly elevated [30, 31].
Oxidative stress-mediated endothelial cell injury and a con-
current increase in CECs are seen in many cardiovascular
diseases, including myocardial infarction, unstable angina
[32], and coronary artery disease [33]. Damani et al. [34]
have characterized CECs using the first automated and
clinically feasible CEC three-channel fluorescence micros-
copy assay in 50 consecutive patients with STEMI and 44
consecutive healthy controls. CEC counts were significantly
elevated in myocardial infarction cases versus controls,
with median numbers of 19 and 4 cells/ml, respectively.
CECs from patients with STEMI are heterogeneous in size
and shape and many of them are much larger than CECs
from controls, with multiple nuclei.
Recent work has suggested that, in addition to its pri-
mary effect on platelet function, clopidogrel has anti-
inflammatory capability [25] and enhances endothelial
production of nitric oxide and prostacyclin in tissue cul-
ture [35]. This, in concert with its ability to inhibit
CD40L both in vitro and in vivo [36], suggests that clo-
pidogrel possesses the ability to preserve endothelial
function by a mechanism that might be independent of
its antiplatelet activity. Among other effects, CD40L
blockade stimulates heme oxygenase 1 expression [37].
McClung et al. [38] observed the influence of clopido-
grel treatment on endothelial function in diabetic pa-
tients. The patients with diabetes mellitus had an
elevated number of CECs (mean 79 ± 15 cells/ml of per-
ipheral blood, range 20 to 110). After 4 weeks of therapy
with clopidogrel, 75 mg/day, a marked reduction in the
number of CECs was observed in all subjects to within
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the normal range (mean 10 ± 4 cells /ml, range 0 to 40;
p < 0.001).
Ticagrelor is an oral, reversible, direct-acting inhibitor
of the adenosine diphosphate receptor P2Y12 that has a
more rapid onset and more pronounced platelet inhib-
ition than clopidogrel. The Platelet Inhibition and Pa-
tient Outcomes (PLATO) trial shows that, in patients
who have an ACS, treatment with ticagrelor as com-
pared with clopidogrel significantly reduced the rate of
death from vascular causes, myocardial infarction, or
stroke. Although several studies have attempted to illus-
trate the reason for the results of the PLATO trial, such
as stating that ticagrelor is dependent on adenosine re-
ceptor activation [39], as of yet there is no identified evi-
dence. So what are the roles of an anti-inflammatory
and the CEC enhancing capability? Is ticagrelor superior
to clopidogrel in these two ways?
The DISPERSE 2 (Dose Confirmation Study Assessing
Anti-Platelet Effects of AZD6140 vs Clopidogrel in
NSTEMI 2) trial [40] has compared ticagrelor with clopi-
dogrel in anti-inflammatory ability. This trial included pa-
tients who were hospitalized for NSTE-ACS within the
48 h before study entry, had ischemic symptoms ≥10 min
at rest, and had either biochemical marker evidence of
myocardial infarction or electrocardiographic evidence of
ischemia. The objective of the analysis from the DIS-
PERSE 2 trial was to compare ticagrelor and clopidogrel
for effects on the inflammatory biomarkers CRP, interleu-
kin 6, myeloperoxidase, and soluble CD40 ligand. The re-
sults showed that CRP levels had increased somewhat at
discharge and were reduced only at 4 weeks. Ticagrelor
and clopidogrel appeared not to differ in this study with
respect to the inflammatory biomarkers in patients with
NSTE-ACS [41]. Differences in timing of the measure-
ments, treatment regimens, or patient conditions could
have affected the results.
As we know, STEMI has a very different pathology
compared with NSTE-ACS [42, 43]. Although numerous
relevant experiments have shown that antiplatelet drugs
have direct or indirect anti-inflammatory and endothelial
protective effects, whether ticagrelor is superior to clopi-
dogrel in anti-inflammatory effect and protection of vas-
cular endothelium is not clear. To the best of our
knowledge, this study will be the first one to compare
the influence of these two drugs on inflammatory bio-
markers and vascular endothelial function for patients
with STEMI receiving emergency PCI.
Methods
Study design
This study (https://clinicaltrials.gov/ct2/home regis-
tration: NCT02123004) is a prospective, open-label, mul-
ticenter, clinical study using continuous monitoring with a
clinical research organization.
The study will be conducted at three clinical centers
in China. Up to 350 patients will be enrolled. Those en-
rolled will be assumed to be patients with STEMI who
are scheduled to undergo emergency PCI. The inclusion
and exclusion criteria are showed in Tables 1 and 2,
respectively.
Enrolled patients will be followed up for ≥ 4 weeks, with
four visits during hospitalization and one visit after dis-
charge. During follow-up, blood samples will be collected.
Ethical conduct of the study and informed consent
Ethical approval was obtained from the Ethical Review
Board of Jinan Central Hospital, the Ethical Review
Board of the People’s Hospital of Shandong Provence,
and the Ethical Review Board of the People’s Hospital of
Dezhou City. The trial will be performed in accordance
with ethical principles according to the Declaration of
Helsinki and are consistent with Good Clinical Practice
a applicable regulatory requirements. They will also be
conducted in compliance with applicable local laws and
regulations of each participating center, including data
protection laws, and any requirements imposed by local
competent authorities, ethics committees, and institu-
tional review boards.
Informed consent is obtained from every participant in
the trial.
Objectives
The trial objectives are a) to observe whether ticagrelor
inhibits inflammation and improves vascular endothelial
cell function to a greater extent than clopidogrel in
STEMI patients whether they receive PCI or not, and b)
to observe whether ticagrelor can reduce the serum
levels of inflammatory biomarkers both in coronary and
in peripheral venous in patients with STEMI or not.
Safety objective
The safety objective of this study in patients will be eval-
uated by the occurrence of any adverse event (AE)
Table 1 Inclusion criteria
For inclusion in the study the subject should fulfill the following criteria:
a) Male or non-pregnant female
b) Age ≥ 18 years old and <80 years old
c) Consecutive patients who should be hospitalized with documented
evidence of STEMI receiving PCI
d) All patients have persistent ⩾ 0.2 mV ST-segment elevation in two or
more contiguous precordial leads or ⩾ 0.1 mV ST elevation in two or
more contiguous limb leads, with one of the following: persistent
chest pain or elevation of biomarkers of myocardial necrosis
e) Time from chest pain onset to receiving PCI <12 h
f) Persistent chest pain <12 h
g) Provision of informed consent prior to any study-specific procedures.
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during the 4 weeks follow-up: Suspected bleeding/rein-
farction/rehospitalization/revascularization by PCI or
coronary artery bypass graft/sudden death/stroke/allergic
or allergic-like reactions, or other AEs and serious ad-
verse events (SAEs).
Study procedures
Patients who are scheduled to undergo emergency PCI
will be randomly assigned to receive a loading dose of
ticagrelor 180 mg as the treatment group or clopidogrel
600 mg as the control group. After PCI, the treatment
group will be treated with ticagrelor 90 mg twice daily
while the control group will be treated with clopidogrel
75 mg once daily. The vascular endothelial function will
be tested by CECs, and levels of inflammation will be
tested by CD40L, hsCRP and P-selectin (see Fig. 1).
Collection of study variables
Recording of data
At visit 1, subjects who provide informed consent for
the study will be assigned a number. After patients meet
all study entry criteria and report to the research unit
for the first treatment period, a unique three-digit sub-
ject number from the randomization code is assigned to
each subject.
Data collection at enrollment and follow-up
Each patient will undergo enrollment procedures at visit
1, and all the variables recorded in the clinical chart will
be source data when the patient is in the hospital. At the
day of discharge, the patients will receive a patient diary
Table 2 Exclusion criteria
Subjects should not enter the study if any of the following exclusion
criteria are fulfilled:
a) Involved in other trials
b) In last year have P2Y12 receptor antagonist drug treatment history
or long-term use of immunosuppressive agents
c) Recurrent myocardial infarction or previous history of CABG surgery
or rescue PCI
d) Active bleeding or bleeding history
e) Obvious infection and body temperature (axillary temperature)
higher than 38.0 °C
f) Autoimmune diseases
g) Malignancies
h) In last 6 months have received major surgery
i) Left ventricular ejection fraction is less than 30 %
j) Life expectancy less than one year.
Fig. 1 Study procedure
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to record investigational medication information and
will be told the follow-up visit date for the laboratory
test and clinical examination. Patients will have routine
visits as outlined in Table 3.
Evaluations that are reported in the Case Report Form
must be supported by appropriately signed identified source
documentation related but not limited to the following:
 Agreement, date, and signature of informed consent
mentioning the study identification.
 Patient identification, last participation in a clinical
trial, medical history, associated diseases, and data
related to the studied pathology.
 Previous and concomitant medication.
 Study identification.
 Treatment number, dates of administration.
 Dates of visits and assessments including the
examination report.
 Vital signs, height, body weight. ECG records signed
and dated.
 Adverse events and follow-up:
In the case of an SAE, the site should file in the
source document at least copies of the hospitalization
reports and any relevant examination reports docu-
menting the follow-up of the SAE.
 Date of premature study discontinuation (if any) and
reason.





Table 3 Data to be collected at routine visits
Screening phase Study phase
Evaluation Screening Follow-up






4 weeks (±3 days)
(after PCI)





Medical/surgical history, allergy history,
alcohol habits, smoking habits
x
Symptom inquiry x x x x x x
Body weight x x
Physical examination x x x x x x
Vital signs: temperature/pulse/respiration/
blood pressure
x x x x x x
18-lead ECG x x x x x x
AE/SAE recording x x x x x x
Treatment adherence x x x x x x
Myocardial necrosis biomarkers x x x x
Laboratory testing/efficacy
CD40l/CRP/P-selectin/CECs x x x x
Laboratory testing/safety
Creatinine x x x x
Uric acid x x x
AST/ALT/TBIL x x x
Blood-routine x x x x
TG/TC/HDL-C/LDL-C x x x
Serum Na+, K+, Cl− x x x x
Urinary albumin x x
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Statistical methods and sample size determination
Description of analysis sets
The primary analysis was proposed to be based on
the intention-to-treat principle. All randomized pa-
tients who had at least one dose of investigational
medication would be included. If a patient withdrew
their informed consent after randomization without
taking any medication, he/she would be excluded
from the analysis. The analysis set according to the
above principle was defined as a modified full analysis
set (mFAS).
If there were other major protocol violations, after the
adjudication by the principle investigator, the corre-
sponding patients would be further excluded from the
per protocol analysis set (PPS).
Efficacy analysis set
The efficacy analysis will be conducted on both the
mFAS and PPS.
Safety analysis set
The safety analysis would be conducted on the mFAS.
Methods of statistical analyses
Categorical variables were described by counts and pro-
portions, and continuous variables were described by
median and interquartile range. Proportions were com-
pared by chi-square tests and continuous outcome by
Mann-Whitney U tests. A two-sided level of significance
of 0.05 was applied to general comparison.
To avoid the multiplicity issue induced by multiple end-
points, the Bonferroni-Holm’s method will be used to con-
trol the overall alpha level. All analyses will be performed
using SAS 9.1.3 (SAS Institute Inc., Cary, NC, USA).
Determination of sample size
 The key endpoints of this study were the changes of
hsCRP, CD40L, P-selectin, and CECs from baseline
to 4 weeks after PCI. The relevant data was limited
in the published literature. For patients with NSTE-
ACS [41] the change of inflammatory markers at
4 weeks had not been observed and the variation of
markers was huge.
 In our study, the target population was patients with
STEMI and PCI. We assume the inflammatory and
endothelial function markers would be different for
ticagrelor and clopidogrel after 4 weeks of
treatment. This study was proposed to detect a
moderate effect size, which means the expected
standardized difference (mean difference/common
standard deviation) between the two treatment
groups was 0.4.
 The fact that there were four key endpoints in this
study led to the multiplicity issue. To control the
overall type I error, the significant level for each
endpoint was set to 0.0125 (0.05/4). Under the
above assumptions, with a two-sided 0.0125 alpha
level and a 20 % dropout rate, 350 patients (175 in
each group) in total would offer 80 % power to
detect the estimated moderate difference between
ticagrelor and clopidogrel among any of the primary
endpoints.
Audits and inspections
Authorized representatives of the institution, a regula-
tory authority, or an ethics committee may perform au-
dits or inspections at the center, including source data
verification.
Discussion
For reasons of economy and the medical care system,
clopidogrel is still the most widely used antiplatelet
medicine in ACS in addition to aspirin [44]. A number
of individuals experience clopidogrel resistance, which
leads to adverse thrombotic events [45]. Although a
study shows that the most common cause of clopido-
grel’s failure in treatment is medication nonadherence,
inter-individual variability in response to clopidogrel is
also an important reason, which is appreciated in up to
30–40 % of patients who received clopidogrel treatment
[46–48]. As another P2Y12R antagonist, ticagrelor is be-
coming a strong competitor to clopidogrel.
Although much progress has been made in the treat-
ment of STEMI, there is still high mortality of patients in
the real world. As a phase III clinical trial, the PLATO trial
compared ticagrelor to clopidogrel in addition to aspirin
in over 18,000 patients with ACS. Results show a signifi-
cant decrease in primary efficacy outcome (composite
endpoint of death from vascular causes, myocardial infarc-
tion, or stroke) at 12 months (9.8 % with ticagrelor versus
clopidogrel 11.7 %; p < 0.001) [49]. The incidence of stent
thrombosis across definitions was reduced in patients re-
ceiving ticagrelor compared with clopidogrel regardless of
type of ACS, presence of diabetes, and stent type [50].
The pathophysiology of ACS is multifactorial. It in-
volves disruption of vulnerable plaque and thrombus
formation, which produces severe myocardial ischemia
and downstream embolization in the coronary vascular
bed, leading to subendocardial or transmural necrosis. All
the above occur in response to inflammation [51, 52].
STEMI is caused by acute total coronary occlusion,
whereas NSTE-ACS is associated with vulnerable plaque
and subocclusive thrombosis. Although the DISPERSE
trial did not find the difference between the two drugs in
NSTE-ACS patients, the big pathology gap between
STEMI and NSTE-ACS deserves more attention to find
the difference in the effects of these two drugs on inflam-
mation and endothelial dysfunction in STEMI patients
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[41]. In addition, more STEMI patients received emer-
gency PCI compared with NSTE-ACS patients, and
STEMI patients will also experience ischemia followed by
rapid reperfusion and are consequently at risk of ische-
mia/reperfusion injury, which will lead to high levels of in-
flammation [53]. After PCI, patients always show better
compliance in taking antiplatelet medicine than no-PCI
patients, so the antiplatelet medicine’s long effect in treat-
ment will be observed in this trial.
To the best of our knowledge, this study is the first
study to compare the influence of ticagrelor and clopido-
grel on inflammatory biomarkers and vascular endothelial
function for patients receiving emergency PCI and will
provide evidence to identify whether or not ticagrelor in-
hibits inflammation and improves vascular endothelial cell
function to a greater extent than clopidogrel.
Trial status
Recruitment began in May 2014 and is ongoing. Seventy
patients have been recruited.
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